Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for chelation therapy as a treatment for atherosclerosis, effective May 15, 2026. Here's what billing teams need to know before claims start hitting the wall.
CMS chelation therapy coverage policy has been a clear non-coverage position for decades — and this 2026 modification doesn't change that core stance. The Centers for Medicare & Medicaid Services continues to treat chelation therapy for atherosclerosis as not reasonable and necessary under Medicare. This policy does not list specific CPT or HCPCS codes in the available data, but billing teams submitting infusion therapy claims tied to atherosclerosis diagnoses need to understand exactly where CMS draws the line — and why crossing it means guaranteed claim denial.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Centers for Medicare & Medicaid Services (CMS) |
| Policy | Chelation Therapy for Treatment of Atherosclerosis |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | Medium — high denial risk for practices offering chelation infusions |
| Specialties Affected | Internal medicine, cardiology, integrative medicine, infusion therapy |
| Key Action | Audit any claims linking chelation infusion codes to atherosclerosis diagnoses before May 15, 2026 |
CMS Chelation Therapy Coverage Criteria and Medical Necessity Requirements 2026
CMS has maintained since its original national determination that chelation therapy for atherosclerosis does not meet the standard for medical necessity under Medicare. The agency's position is grounded in the lack of sufficient clinical evidence to support chelation — typically administered as EDTA (ethylene diamine tetraacetic acid) infusions — as a safe and effective treatment for cardiovascular disease or atherosclerotic conditions.
The real issue here is the medical necessity threshold. CMS requires that a service be reasonable and necessary for the diagnosis or treatment of illness or injury. Chelation therapy for atherosclerosis has never cleared that bar in CMS's view — not in the original determination, and not in this 2026 modification.
This coverage policy applies broadly across Medicare. Whether you're billing through a Medicare Advantage plan or traditional fee-for-service, the non-coverage position follows. Some Medicare Advantage plans may have their own supplemental benefit language, but don't assume a plan covers what CMS explicitly excludes — verify coverage at the plan level before billing.
Prior authorization won't save you here. This isn't a service where obtaining prior auth converts a non-covered item into a covered one. A non-covered service is non-covered regardless of prior authorization status. If a patient wants chelation therapy for atherosclerosis and insists on Medicare billing, the correct path is an Advance Beneficiary Notice of Noncoverage (ABN) — not a prior auth request.
CMS Chelation Therapy Exclusions and Non-Covered Indications
CMS's position on chelation for atherosclerosis is clear: not covered. The therapy lacks the clinical evidence base CMS requires for reimbursement under Medicare.
The non-coverage designation here is specific to atherosclerosis as the indication. Chelation therapy does have legitimate, covered uses under Medicare — heavy metal poisoning is the primary example. Lead toxicity, arsenic poisoning, iron overload — these are conditions where chelation is clinically established and covered. The problem arises when practitioners or patients push chelation as a cardiovascular intervention, which is where CMS draws the hard line.
Integrative medicine practices need to pay particular attention. The pitch for chelation as an atherosclerosis treatment has persisted in some clinical circles despite the evidence gaps. CMS isn't persuaded by that pitch, and your claim won't be either. If a patient presents with both a cardiovascular condition and heavy metal toxicity, code for the heavy metal indication — not the atherosclerosis. Diagnosis coding drives coverage here, and the wrong ICD-10 selection will trigger denial regardless of the infusion administered.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Atherosclerosis / cardiovascular disease | Not Covered | Not specified in policy data | CMS determination: not reasonable and necessary |
| Heavy metal poisoning (e.g., lead, arsenic) | Covered (separate determination) | Not specified in this policy | Covered under different CMS authority — distinct clinical indication |
| Chelation as investigational cardiovascular therapy | Not Covered | Not specified in policy data | Does not meet medical necessity standard; ABN required if patient elects treatment |
Note: This policy does not list specific CPT or HCPCS codes. See the Affected Codes section below for guidance.
CMS Chelation Therapy Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Pull and review any chelation infusion claims submitted in the last 12 months. Look specifically for claims where the diagnosis codes point to atherosclerosis, coronary artery disease, or peripheral vascular disease. Those claims are at risk. Do this before May 15, 2026. |
| 2 | Issue ABNs for any patient requesting chelation therapy for cardiovascular indications. The ABN must be completed before the service is rendered — not after. If the patient signs and elects to proceed, they own the cost. If you skip the ABN, you may not be able to collect from the patient either. |
| 3 | Verify the indication before billing any chelation infusion. Heavy metal poisoning is covered. Atherosclerosis is not. The diagnosis code on the claim is what CMS evaluates. Make sure your documentation supports the coded diagnosis — and that the coded diagnosis is the actual clinical reason for treatment. |
| 4 | Train your front desk and scheduling staff on this distinction. If patients call requesting chelation "for their heart," your intake process should flag that immediately. This isn't a clinical gray area — it's a billing compliance issue. Staff who schedule these cases without flagging the indication create downstream claim denial problems. |
| 5 | Check your Medicare Advantage contracts. Some MA plans issue their own coverage policies that mirror CMS's national positions. Others add supplemental benefits or vary on coverage terms. Don't assume. Pull the specific plan's chelation therapy billing guidelines before submitting any claim. |
| 6 | Document, document, document. If you're treating heavy metal toxicity in a patient who also has atherosclerosis, your clinical notes must clearly support the heavy metal diagnosis as the primary reason for chelation. CMS auditors and Medicare Administrative Contractors look at the totality of the record. A chart that reads like a cardiovascular workup won't support a heavy metal poisoning claim. |
| 7 | Talk to your compliance officer before the effective date if your practice offers chelation regularly. This modification may signal renewed audit attention on chelation claims. If chelation infusions represent meaningful revenue in your practice, a proactive compliance review before May 15, 2026, is worth the time. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Chelation Therapy Under CMS Policy
Important Note on Code Data
This policy does not list specific CPT, HCPCS, or ICD-10 codes in the available policy data. Do not infer covered or non-covered status from code descriptions alone.
That said, billing teams working with chelation therapy should be aware of how these claims typically flow — and where diagnosis coding creates coverage exposure.
Common Codes Associated With Chelation Infusions (for reference — not from policy data)
The policy data for this CMS determination does not include a code list. If you bill chelation therapy, work directly with your Medicare Administrative Contractor or compliance officer to confirm current code-level guidance. The MAC-level local coverage determinations in your region may have additional specificity on which codes trigger review.
Why This Matters for Your Code Selection
The absence of a code list in this policy doesn't mean code selection is irrelevant. CMS's coverage determination applies at the indication level — meaning the ICD-10 diagnosis code linked to the claim is what triggers coverage or denial review.
Pairing a chelation infusion code with an atherosclerosis ICD-10 — codes in the I70.x range for arteriosclerosis, for example — will flag the claim against this non-coverage determination. Pairing the same infusion code with a heavy metal poisoning diagnosis — T56.x range for toxic effects of metals — puts you in different coverage territory entirely.
The code on the claim tells CMS what you're treating. Make sure it's accurate and supported by your documentation.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.